Cat. No.: HY-111361

FN-1501

(Synonyms: LT-171-861)

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

FN-1501 is a potent inhibitor of FLT3 and CDK, with IC₅₀s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.

For research use only. We do not sell to patients.

Purity: 98.72%
CAS No.: 1429515-59-2
Formula: C₂₂H₂₅N₉O
Molecular Weight:431.49

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

FN-1501 Chemical Structure

CAS No.: 1429515-59-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

Cdk4/cyclin D1

0.85 nM (IC₅₀)

CDK6/cyclinD1

1.96 nM (IC₅₀)

cdk2/cyclin A

2.47 nM (IC₅₀)

FLT3

0.28 nM (IC₅₀)

All CDK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
BaF3	IC₅₀	0.008 μM Compound: FN-1501	Antiproliferative activity against mouse BaF3 cells harboring FLT3 ITD/D835V mutant assessed as inhibition of cell growth incubated for 72 hrs Antiproliferative activity against mouse BaF3 cells harboring FLT3 ITD/D835V mutant assessed as inhibition of cell growth incubated for 72 hrs	[PMID: 37163951]
BaF3	IC₅₀	0.038 μM Compound: FN-1501	Antiproliferative activity against mouse BaF3 cells harboring FLT3 ITD mutant assessed as inhibition of cell growth incubated for 72 hrs Antiproliferative activity against mouse BaF3 cells harboring FLT3 ITD mutant assessed as inhibition of cell growth incubated for 72 hrs	[PMID: 37163951]
BaF3	IC₅₀	0.039 μM Compound: FN-1501	Antiproliferative activity against mouse BaF3 cells harboring FLT3 D835V mutant assessed as inhibition of cell growth incubated for 72 hrs Antiproliferative activity against mouse BaF3 cells harboring FLT3 D835V mutant assessed as inhibition of cell growth incubated for 72 hrs	[PMID: 37163951]
BaF3	IC₅₀	0.056 μM Compound: FN-1501	Antiproliferative activity against mouse BaF3 cells harboring FLT3 ITD/F691L mutant assessed as inhibition of cell growth incubated for 72 hrs Antiproliferative activity against mouse BaF3 cells harboring FLT3 ITD/F691L mutant assessed as inhibition of cell growth incubated for 72 hrs	[PMID: 37163951]
BaF3	IC₅₀	0.073 μM Compound: FN-1501	Antiproliferative activity against mouse BaF3 cells harboring FLT3 ITD/N676D mutant assessed as inhibition of cell growth incubated for 72 hrs Antiproliferative activity against mouse BaF3 cells harboring FLT3 ITD/N676D mutant assessed as inhibition of cell growth incubated for 72 hrs	[PMID: 37163951]
BaF3	IC₅₀	0.155 μM Compound: FN-1501	Cytotoxicity against mouse BaF3 cells assessed as inhibition of cell growth incubated for 72 hrs Cytotoxicity against mouse BaF3 cells assessed as inhibition of cell growth incubated for 72 hrs	[PMID: 37163951]
BaF3	IC₅₀	7.65 nM Compound: 4; FN.1501	Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-F691L mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiterGlo luminescent assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-F691L mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiterGlo luminescent assay	[PMID: 34550682]
BT-474	IC₅₀	23939 nM Compound: CICAMPA-07	Cytotoxicity against human BT-474 cells incubated for 48 hrs by CCK-8 reagent microplate reader assay Cytotoxicity against human BT-474 cells incubated for 48 hrs by CCK-8 reagent microplate reader assay	[PMID: 36827953]
HCT-116	GI₅₀	0.09 μM Compound: 50; FN-1501	Growth inhibition of human HCT116 cells after 72 hrs by CellTiter-Glo assay Growth inhibition of human HCT116 cells after 72 hrs by CellTiter-Glo assay	[PMID: 29357250]
HL-60	IC₅₀	770.1 nM Compound: FN-1501	Antiproliferative activity against human HL-60 cells expressing low level wild type FLT3 assessed as inhibition of cell growth Antiproliferative activity against human HL-60 cells expressing low level wild type FLT3 assessed as inhibition of cell growth	[PMID: 37163951]
HL-60	IC₅₀	89.33 nM Compound: FN-1501	Antiproliferative activity against human HL-60 cells measured after 1 to 3 days by CCK-8 assay Antiproliferative activity against human HL-60 cells measured after 1 to 3 days by CCK-8 assay	[PMID: 38878515]
K562	IC₅₀	795.1 nM Compound: FN-1501	Antiproliferative activity against human K562 cells deficit of oncogenic FLT3 assessed as inhibition of cell growth Antiproliferative activity against human K562 cells deficit of oncogenic FLT3 assessed as inhibition of cell growth	[PMID: 37163951]
Lymphocyte	IC₅₀	0.492 μM Compound: 50; FN-1501	Cytotoxicity against human lymphocytes assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human lymphocytes assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 29357250]
MCF7	GI₅₀	2.84 μM Compound: 50; FN-1501	Growth inhibition of human MCF7 cells after 72 hrs by CellTiter-Glo assay Growth inhibition of human MCF7 cells after 72 hrs by CellTiter-Glo assay	[PMID: 29357250]
MGC-803	GI₅₀	0.37 μM Compound: 50; FN-1501	Growth inhibition of human MGC803 cells after 72 hrs by CellTiter-Glo assay Growth inhibition of human MGC803 cells after 72 hrs by CellTiter-Glo assay	[PMID: 29357250]
MOLM-13	IC₅₀	5.4 nM Compound: FN-1501	Antiproliferative activity against human MOLM-13 cells harboring FLT3 ITD mutant assessed as inhibition of cell growth Antiproliferative activity against human MOLM-13 cells harboring FLT3 ITD mutant assessed as inhibition of cell growth	[PMID: 37163951]
MV4-11	IC₅₀	0.004 μM Compound: 3; FN-1501	Synergistic antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs in presence vorinostat by CellTiterGlo assay Synergistic antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs in presence vorinostat by CellTiterGlo assay	[PMID: 37659198]
MV4-11	IC₅₀	0.007 μM Compound: 3; FN-1501	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by CellTiterGlo assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by CellTiterGlo assay	[PMID: 37659198]
MV4-11	IC₅₀	0.007 μM Compound: FN-1501	Antiproliferative activity against human MV4-11 cells harboring FLT3 ITD mutant assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay Antiproliferative activity against human MV4-11 cells harboring FLT3 ITD mutant assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay	[PMID: 37163951]
MV4-11	IC₅₀	0.008 μM Compound: 50; FN-1501	Growth inhibition of human MV4-11 cells after 72 hrs by CellTiter-Glo assay Growth inhibition of human MV4-11 cells after 72 hrs by CellTiter-Glo assay	[PMID: 29357250]
MV4-11	IC₅₀	6.38 nM Compound: 4; FN.1501	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiterGlo luminescent assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiterGlo luminescent assay	[PMID: 34550682]
MV4-11	IC₅₀	7.02 nM Compound: 3; FN-1501	Antiproliferative activity against human MV4-11 cells expressing FLT3 ITD mutant assessed as inhibition of cell viability incubated for 72 hrs by Cell Titer Glo assay Antiproliferative activity against human MV4-11 cells expressing FLT3 ITD mutant assessed as inhibition of cell viability incubated for 72 hrs by Cell Titer Glo assay	[PMID: 38387337]
NCI-H82	GI₅₀	0.11 μM Compound: 50; FN-1501	Growth inhibition of human NCI-H82 cells after 72 hrs by CellTiter-Glo assay Growth inhibition of human NCI-H82 cells after 72 hrs by CellTiter-Glo assay	[PMID: 29357250]
NCI-H929	IC₅₀	0.58 μM Compound: 55	Cytotoxicity against human NCI-H929 cells assessed as reduction in cell viability measured after 96 hrs by CellTiter-Glo luminescent assay Cytotoxicity against human NCI-H929 cells assessed as reduction in cell viability measured after 96 hrs by CellTiter-Glo luminescent assay	[PMID: 38071792]
PBMC	IC₅₀	126.3 nM Compound: FN-1501	Cytotoxicity against human PBMC cells assessed as inhibition of cell growth Cytotoxicity against human PBMC cells assessed as inhibition of cell growth	[PMID: 37163951]
PC-3	IC₅₀	0.69 μM Compound: FN-1501	Antiproliferative activity against AR-negative human PC3 cells assessed as reduction in cell viability after 5 days by CCK8 assay Antiproliferative activity against AR-negative human PC3 cells assessed as reduction in cell viability after 5 days by CCK8 assay	[PMID: 31846828]
RPMI-8226	IC₅₀	3.17 μM Compound: 55	Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability measured after 96 hrs by CellTiter-Glo luminescent assay Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability measured after 96 hrs by CellTiter-Glo luminescent assay	[PMID: 38071792]
RS4-11	GI₅₀	0.05 μM Compound: 50; FN-1501	Growth inhibition of human RS4:11 cells after 72 hrs by CellTiter-Glo assay Growth inhibition of human RS4:11 cells after 72 hrs by CellTiter-Glo assay	[PMID: 29357250]
U-266	IC₅₀	0.78 μM Compound: 55	Cytotoxicity against human U-266 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human U-266 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38071792]

In Vitro

FN-1501 is a potent inhibitor of FLT3 and CDK, with IC₅₀s of 2.47 ± 0.21, 0.85 ± 0.28, 1.96 ± 0.08 and 0.28 ± 0.01 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 shows potent inhibitory activity against several tumor cells, such as MGC803, RS4 11, MCF-7, HCT-116, and NCI-H82, with GI₅₀s of 0.37 ± 0.04, 0.05 ± 0.01, 2.84 ± 0.25, 0.09 ± 0.04, 0.11 ± 0.02 nM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

FN-1501 exhibits potent antitumor activity, and shows little cytotoxicity on normal lymphocyte cells, with LD₅₀ of 185.67 mg/kg in ICR mice. FN-1501 (15. 30, or 40 mg/kg/d, i.v.) dose-dependently and significantly suppresses the growth of tumor in MV4-11-cell-inoculated-xenograft mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 1429515-59-2
Appearance Solid
Molecular Weight 431.49
Formula C₂₂H₂₅N₉O
Color White to off-white
SMILES

O=C(C1=NNC=C1NC2=NC=NC3=C2C=CN3)NC4=CC=C(CN5CCN(C)CC5)C=C4
Synonyms

LT-171-861
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

Comput Biol Med

Synergy and antagonism between azacitidine and FLT3 inhibitors. [Abstract]

2024 Feb:169:107889. PMID: 38199214
Bioorg Chem

Inhibition of FLT3-induced signalling in refractory acute myeloid leukaemia. [Abstract]

2025 Apr 5:160:108424. PMID: 40209351

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL (115.88 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3176 mL

11.5878 mL

23.1755 mL

5 mM

0.4635 mL

2.3176 mL

4.6351 mL

10 mM

0.2318 mL

1.1588 mL

2.3176 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (5.79 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Kinase Assay^[1]

The activity of the CDKs and FLT3 are assayed in reaction buffer (20 mM HEPES pH 7.5, 10 mM MgCl₂, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na₃VO₄, 2 mM DTT, 1% DMSO) at room temperature at a final ATP concentration of 10 mM. Then FLT3, dissolved in 100% DMSO at the indicated doses, are delivered into the kinase reaction mixture by acoustic technology and incubated for 20 min at room temperature. After 10 μM [γ-³³P] ATP (specific activity 10 Ci/μL) is added to initiate the reaction, the reactions are carried out at 25°C for 120 min. The kinase activities are detected by the filterbinding method. IC₅₀ values and curve fits are obtained by Prism^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

The human AML cell line MV4-11 is cultured in IMDM media with 10% FBS and supplemented with 2% l-glutamine and 1% penicillin/streptomycin. The MV4-11 cell line is maintained in culture media at 37°C with 5% CO₂. The effects of FN-1501 on MV4-11 proliferation are performed. Cells are cultured in 96-well culture plates (10 000 cells/well). FN-1501 at various concentrations is added to the plates. Cell proliferation is determined after treatment with FN-1501 for 72 h. Cell viability is measured using the CellTiter-Glo assay, and luminescence is measured in a multilabel reader. Data are normalized to control groups (DMSO) and represented as the means of three independent measurements with standard errors of <20%. IC₅₀ values are calculated using Prism 5.0^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice^[1]
Six-week-old female nu/nu mice are housed in a specific pathogen-free facility. Prior to implantation, cells are harvested during exponential growth. Five million MV4-11 cells in PBS are formulated as a 1:1 mixture with a Matrigel and injected into the subcutaneous space on the right flank of each nu/nu mouse. Daily intravenous injections are initiated when MV4-11 tumors have reached sizes of 100-200 mm³. The animals are then randomized into treatment groups of 8 mice each for the efficacy studies and dosed with FN-1501 (0, 15, 30, or 40 (mg/kg)/d) or cytarabine (50 (mg/kg)/d). The compounds (FN-1501, etc.) are dissolved in a solution of PEG400 (25%), ethanol (3.7%), glucose (5%), and acetic acid/sodium acetate buffer (pH 4.5, 7.5%). Tumor growth is measured every 3 days using Vernier calipers for the duration of the treatment. The volume is calculated as follows: tumor volume = a × b²/2, where a is the long diameter, and b is the short diameter. The percentage of tumor-growth inhibition (GI) is calculated as follows: GI = 100% × {1 - [(tumor volumefinal - tumor volumeinitial for the compound-treated group)/(tumor volumefinal - tumor volumeinitial for the vehicle-treated group)]}. The percent tumor regression (PTR) is calculated as follows: PTR = 100% × (tumor volumeinitial - tumor volumefinal)/(tumor volumeinitial)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Wang Y, et al. Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3176 mL	11.5878 mL	23.1755 mL	57.9388 mL
	5 mM	0.4635 mL	2.3176 mL	4.6351 mL	11.5878 mL
	10 mM	0.2318 mL	1.1588 mL	2.3176 mL	5.7939 mL
	15 mM	0.1545 mL	0.7725 mL	1.5450 mL	3.8626 mL
	20 mM	0.1159 mL	0.5794 mL	1.1588 mL	2.8969 mL
	25 mM	0.0927 mL	0.4635 mL	0.9270 mL	2.3176 mL
	30 mM	0.0773 mL	0.3863 mL	0.7725 mL	1.9313 mL
	40 mM	0.0579 mL	0.2897 mL	0.5794 mL	1.4485 mL
	50 mM	0.0464 mL	0.2318 mL	0.4635 mL	1.1588 mL
	60 mM	0.0386 mL	0.1931 mL	0.3863 mL	0.9656 mL
	80 mM	0.0290 mL	0.1448 mL	0.2897 mL	0.7242 mL
	100 mM	0.0232 mL	0.1159 mL	0.2318 mL	0.5794 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

FN-1501

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Membrane Protein-targeted Compound Library

Cytokine Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) FN-1501

All CDK Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

FN-1501

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Membrane Protein-targeted Compound Library

Cytokine Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) FN-1501

All CDK Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

FN-1501 Related Classifications

Cat. No.: HY-111361